As reported on World Pharma News, the U.S. Food and Drug Administration has granted approval to daraxonrasib, an oral RAS-targeting therapy, for adults with metastatic pancreatic adenocarcinoma who have previously received systemic treatment or are not suitable candidates for multiagent chemotherapy. The regulatory decision was largely supported by data from the phase 3 RASolute 302 study, an international trial led by Brian Wolpin, MD, MPH, of Dana-Farber Cancer Institute.
The approval is being viewed as a major breakthrough in a disease area where treatment advances have historically been limited. Researchers have spent decades attempting to directly interfere with RAS-driven cancer growth, recognizing the pathway as a central driver of pancreatic cancer biology. Despite its importance, developing therapies capable of effectively disrupting RAS signaling proved difficult for many years.
Daraxonrasib becomes the first approved targeted treatment for pancreatic cancer specifically designed to inhibit RAS activity. The drug works by forming a molecular complex with cyclophilin A, preventing RAS proteins from transmitting the signals that promote tumor growth and survival. Mutations in KRAS, a member of the RAS gene family, are found in more than 90% of pancreatic cancer cases, making the pathway an attractive therapeutic target.
The phase 3 RASolute 302 trial enrolled 500 patients with metastatic pancreatic cancer from sites in North America, Europe, and Asia. All participants had previously received one chemotherapy regimen for metastatic disease. Patients were randomly assigned to receive either daraxonrasib or physician-selected second-line chemotherapy.
Trial findings demonstrated a significant survival benefit for patients treated with the targeted therapy. Daraxonrasib reduced the risk of death by 60% compared with chemotherapy, corresponding to a hazard ratio of 0.40. Median overall survival reached 13.2 months in the daraxonrasib group, compared with 6.7 months among patients receiving standard chemotherapy.
Investigators also reported meaningful improvements in disease control. Median progression-free survival was 7.2 months for patients taking daraxonrasib, double the 3.6 months observed in the chemotherapy arm, indicating a substantial delay in tumor progression.
Response rates were likewise higher with the novel therapy. Across the entire study population, the objective response rate was 31.6% among patients receiving daraxonrasib, versus 11.2% for those treated with chemotherapy. In the subgroup of patients with confirmed RAS G12 mutations, objective responses occurred in 33.2% of participants receiving daraxonrasib compared with 11.8% of those given chemotherapy.
Results from the trial were presented at the 2026 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine. According to investigators, the safety profile remained consistent with findings from earlier clinical research. No unexpected adverse events were identified, and the most frequently reported treatment-related side effects included rash, oral mucosal inflammation, nausea, and diarrhea.
Study leader Wolpin described the approval as a pivotal moment for the pancreatic cancer community, noting that the nearly twofold increase in median overall survival represents a meaningful improvement for patients facing a disease with few effective treatment options.
Dana-Farber leadership also highlighted the significance of the milestone. The institution played a key role in both the laboratory research and clinical development efforts that ultimately led to the drug’s approval, underscoring the impact of long-term investment in cancer science and translational research.
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, remains one of the deadliest malignancies worldwide. Approximately 65,000 Americans are diagnosed with the disease each year, while annual deaths exceed 50,000. Because early-stage pancreatic cancer often produces few noticeable symptoms, roughly four out of five patients are diagnosed only after the cancer has spread locally or metastasized, limiting available treatment options. For those with metastatic disease, the five-year relative survival rate is about 3% in the United States.
Researchers believe the approval of daraxonrasib may signal the beginning of a new treatment era for pancreatic cancer. Ongoing efforts are focused on building upon this advance by developing additional strategies that can extend responses, improve long-term outcomes, and ultimately increase the number of patients who achieve durable disease control or cure.
